Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $123.0 million.

  • Artiva Biotherapeutics' Cash & Equivalents rose 12011.06% to $123.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.0 million, marking a year-over-year increase of 12011.06%. This contributed to the annual value of $40.2 million for FY2024, which is 2480.0% down from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Cash & Equivalents stood at $123.0 million, which was up 12011.06% from $142.4 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Cash & Equivalents high stood at $166.0 million for Q1 2025, and its period low was $34.2 million during Q2 2024.
  • Its 3-year average for Cash & Equivalents is $78.3 million, with a median of $54.8 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 3621.75% in 2024, then skyrocketed by 31579.07% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Cash & Equivalents (Quarter) stood at $53.5 million in 2023, then fell by 24.8% to $40.2 million in 2024, then skyrocketed by 205.7% to $123.0 million in 2025.
  • Its Cash & Equivalents was $123.0 million in Q3 2025, compared to $142.4 million in Q2 2025 and $166.0 million in Q1 2025.